Biocept Inc (BIOC)

1.42
0.01 0.71
NASDAQ : Health Care
Prev Close 1.41
Open 1.41
Day Low/High 1.32 / 1.45
52 Wk Low/High 0.56 / 2.76
Volume 443.56K
Avg Volume 717.40K
Exchange NASDAQ
Shares Outstanding 26.60M
Market Cap 37.24M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept's Target Selector Platform Featured In Three Clinical Abstracts At The 2017 American Society Of Clinical Oncology Annual Meeting Where Company Plans To Launch New Marketing Campaign

Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsy

The Addario Lung Cancer Medical Institute And Biocept Announce Collaboration And Initiation Of Landmark ALCMI-009 Liquid Biopsy Clinical Trial In Lung Cancer

Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancer

Biocept Awarded Additional Patent In Japan Expanding Intellectual Property Estate To 19 Issued Patents Protecting Its Target Selector™ Liquid Biopsy Platform

New patent provides broad coverage for the use of antibodies to capture targets of interest, including circulating tumor cells (CTCs) and other materials shed by solid tumors into the blood stream

Biocept Announces Collaboration With The OHSU Knight Cancer Institute To Increase Clinical Adoption Of Liquid Biopsy Testing And To Co-Develop Additional Assay Platform Capabilities

NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of Oregon

Biocept Announces Revised Presentation Time At The 27th Annual Oppenheimer Healthcare Conference

Company presentation set for March 22 at 1:00 p.m. ET

Biocept And Catalyst Pharmaceuticals Collaborate To Provide Liquid Biopsy Testing For Small Cell Lung Cancer To Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Biocept's CEO Issues Letter To Stockholders

Highlights key accomplishments and outlines value drivers for 2017

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids

Columbia University Medical Center Sponsors Clinical Study Using Biocept's Liquid Biopsy Platform To Evaluate Cerebrospinal Fluid Of Breast Cancer Patients For Metastatic Biomarkers

Columbia University Medical Center Sponsors Clinical Study Using Biocept's Liquid Biopsy Platform To Evaluate Cerebrospinal Fluid Of Breast Cancer Patients For Metastatic Biomarkers

Study designed to address the significant medical need for rapidly and accurately diagnosing brain metastases in breast cancer patients to enable better treatment decisions

Clinical Utility Of Biocept's Liquid Biopsy Platform Demonstrated In Study Results Presented At The 2016 San Antonio Breast Cancer Symposium

Clinical Utility Of Biocept's Liquid Biopsy Platform Demonstrated In Study Results Presented At The 2016 San Antonio Breast Cancer Symposium

High concordance of the Company's Target-Selector™ platform enables real-time monitoring of key biomarkers in metastatic breast cancer, and provides an alternative when tissue biopsy is not an option

Biocept Presents Robust Analytical Validation Study Results For Its PD-L1 Liquid Biopsy Test At The 17th IASLC World Conference On Lung Cancer

Biocept Presents Robust Analytical Validation Study Results For Its PD-L1 Liquid Biopsy Test At The 17th IASLC World Conference On Lung Cancer

Results demonstrate high level of analytical sensitivity and specificity for the Company's non-invasive, clinically actionable biomarker test for immunotherapy

Study Results Presented At The 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance With Biocept's CtDNA Liquid Biopsy Platform Vs. Tissue Biopsy

Study Results Presented At The 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance With Biocept's CtDNA Liquid Biopsy Platform Vs. Tissue Biopsy

Target Selector™ platform delivers 90% concordance and capability to rapidly detect EGFR, ALK, BRAF, and ROS1 alterations in non-small cell lung cancer patients